Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma

• Michelle Kinder,
• Nizar J. Bahlis,
• Fabio Malavasi,
• Bart de Goeij,
• Alexander Babich,
• Jocelyn Sendecki,
• Joshua Rusbuldt,
• Kevin Bellew,
• Colleen Kane,
• Niels W.C.J. van de Donk

Affiliations

Michelle Kinder

Janssen Research and Development, LLC, Spring House, PA

Nizar J. Bahlis

University of Calgary, Arnie Charbonneau Cancer Institute, Calgary

Fabio Malavasi

Department of Medical Science, University of Turin, Turin, Italy, and Fondazione Ricerca Molinette, Turin

Bart de Goeij

Genmab B.V., Utrecht

Alexander Babich

Janssen Research and Development, LLC, Spring House, PA

Jocelyn Sendecki

Janssen Research and Development, LLC, Spring House, PA

Joshua Rusbuldt

Janssen Research and Development, LLC, Spring House, PA

Kevin Bellew

Janssen Research and Development, LLC, Spring House, PA

Colleen Kane

Janssen Research and Development, LLC, Spring House, PA

Niels W.C.J. van de Donk

Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam